Gufic Biosciences Limited (BOM:509079)
India
· Delayed Price · Currency is INR | Market Cap | 29.04B |
| Revenue (ttm) | 8.97B |
| Net Income (ttm) | 500.38M |
| Shares Out | 100.28M |
| EPS (ttm) | 4.99 |
| PE Ratio | 58.07 |
| Forward PE | n/a |
| Dividend | 0.10 (0.03%) |
| Ex-Dividend Date | Sep 22, 2025 |
| Volume | 988 |
| Average Volume | 1,610 |
| Open | 293.00 |
| Previous Close | 292.95 |
| Day's Range | 289.00 - 294.00 |
| 52-Week Range | 267.50 - 409.00 |
| Beta | -0.08 |
| RSI | 46.37 |
| Earnings Date | May 29, 2026 |
About Gufic Biosciences
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (P... [Read more]
Financial Performance
In fiscal year 2025, Gufic Biosciences's revenue was 8.20 billion, an increase of 1.63% compared to the previous year's 8.07 billion. Earnings were 696.50 million, a decrease of -19.14%.
Financial StatementsNews
Gufic Biosciences Ltd (BOM:509079) Q3 2026 Earnings Call Highlights: Resilient Turnover Amid ...
Gufic Biosciences Ltd (BOM:509079) Q3 2026 Earnings Call Highlights: Resilient Turnover Amid Strategic Shifts
Q3 2026 Gufic Biosciences Ltd Earnings Call Transcript
Q3 2026 Gufic Biosciences Ltd Earnings Call Transcript
Gufic Biosciences Transcript: Q3 25/26
Q3 FY26 saw flat sequential revenue and margins, with export growth offset by domestic operational changes and debtor corrections. Indore ramp-up and regulatory approvals are set to drive 15%+ growth and margin expansion in FY27, with export revenue from Europe expected to begin in Q3/Q4.
Gufic Biosciences Ltd (BOM:509079) Q2 2026 Earnings Call Highlights: Steady Revenue Growth and ...
Gufic Biosciences Ltd (BOM:509079) Q2 2026 Earnings Call Highlights: Steady Revenue Growth and Strategic International Expansion
Q2 2026 Gufic Biosciences Ltd Earnings Call Transcript
Q2 2026 Gufic Biosciences Ltd Earnings Call Transcript
Gufic Biosciences Transcript: Q2 25/26
Revenue and margins improved sequentially, driven by Indore facility ramp-up and strong international growth. Indore contributed all incremental revenue, with capacity utilization at 23-25%. CMO and domestic segments are set for further growth as more clients transition and new products launch.
Gufic Biosciences Transcript: Q1 25/26
Revenue grew 10% sequentially to INR 226.96 crore, driven by the Indore facility ramp-up and strong export momentum. EBITDA and profit margins improved, with further gains expected as capacity utilization and exports increase. Indore is set to become a margin accretive asset from FY 2027.
Gufic Biosciences Transcript: Q4 24/25
Revenue and EBITDA grew modestly year-over-year, but margins declined due to higher fixed costs from the new Indoor facility. International and botulinum toxin businesses are set for strong growth, with Indoor expected to reach EBITDA break-even in FY26 and full ramp-up by FY28.
Gufic Biosciences Ltd (BOM:509079) Q3 2025 Earnings Call Highlights: Navigating Profitability ...
Gufic Biosciences Ltd (BOM:509079) Q3 2025 Earnings Call Highlights: Navigating Profitability Challenges Amidst Strategic Expansions
Q3 2025 Gufic Biosciences Ltd Earnings Call Transcript
Q3 2025 Gufic Biosciences Ltd Earnings Call Transcript
Gufic Biosciences Transcript: Q3 24/25
Q3 FY25 saw stable revenues and margins, with new product launches in fertility and critical care driving growth. Indore facility began production, with ramp-up and break-even expected over the next year, while margin pressure persists due to expansion costs.
Gufic Biosciences Transcript: Q2 24/25
Revenue and profit margins remained stable despite a slight YoY decline, as the Indore facility began phased production with minimal FY25 impact. Strategic business units expanded, and international growth was supported by new approvals and a UK NHS tender.
Gufic Biosciences Transcript: Q1 24/25
Q1 FY25 saw modest revenue and profit growth, with stable margins amid capacity constraints. Indore facility validation is nearly complete, with commercial production set to drive scale, margin expansion, and export growth. Debt is stable, with deleveraging planned as new capacity ramps up.